CRISPR 기반 유전자 편집 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

CRISPR-based Gene Editing Market Size, Share & Trends Analysis Report By Product & Service (CRISPR Kits & Reagents), By Application (Biomedical, Agricultural), By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,521,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,953,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,818,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

CRISPR 기반 유전자 편집 시장 요약

전 세계 CRISPR 기반 유전자 편집 시장 규모는 2024년 40억 1,000만 달러로 추정되며, 2025년부터 2033년까지 CAGR 14.7%로 성장하여 2033년에는 135억 달러에 달할 것으로 예상됩니다.

이러한 성장의 원동력은 유전성 질환의 유병률 증가, 연구 및 기술 발전, 정부 지원책, 바이오테크놀러지에 대한 투자 증가 등입니다.

CRISPR 기술 및 응용의 발전

CRISPR 기술과 응용의 발전은 유전자 편집의 정확성, 효율성, 범용성을 높여 시장 성장을 크게 가속화하고 있습니다. CRISPR-Cas 시스템은 발견 이후 기본적인 DNA 절단을 넘어 정교한 유전체 엔지니어링 플랫폼으로 진화해 왔습니다. CRISPR-Cas 시스템은 고충실도 Cas 변이체, 염기교정, 프라임 편집, 지질 나노입자 및 바이러스 벡터 등 전달 메커니즘의 개선과 같은 기술 혁신에 의해 뒷받침되고 있습니다. 이러한 개선으로 오프 타겟 효과가 감소하고 편집 효율이 향상되었으며, 치료 가능한 병태의 범위가 넓어졌습니다. 인공지능(AI) 및 머신러닝과의 통합을 통해 가이드 RNA 설계 및 표적 부위 선택이 더욱 최적화되어 보다 빠르고 정확한 개발 주기가 가능해졌습니다. 또한, 기술의 적응성은 다중 편집을 지원하여 복잡한 질병이나 형질에 대응하는 데 필수적인 여러 유전자의 동시 변형을 가능하게 합니다.

이러한 발전으로 CRISPR은 인간 치료제 외에도 농업, 산업 생명공학, 진단, 환경 관리 등 새로운 응용 분야로 확대되고 있습니다. 농업 분야에서 CRISPR은 기후변화에 강하고, 해충에 강하고, 영양가가 높은 작물을 만드는 데 적용되어 식량 안보 문제에 대한 해결책을 제공하고 있습니다. 진단학에서는 셜록(SHERLOCK), 펠루다(FELUDA)와 같은 CRISPR 기반 도구가 감염병을 신속하고 저렴한 비용으로 검출할 수 있게 해줍니다. 동시에 합성생물학에서 CRISPR은 지속가능한 바이오연료 및 물질 생산을 위한 미생물 공학에 활용되고 있습니다. CRISPR의 응용 범위의 확대는 지속적인 기술 개선과 함께 제약회사, 농업 생명공학 기업, 연구기관으로부터 강력한 투자를 유치하고 있습니다. 이러한 지속적인 혁신 주기는 대응 가능한 시장을 확대하고, CRISPR이 여러 산업 분야에서 혁신적인 기술 플랫폼으로서의 입지를 강화하는 데 기여하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 CRISPR 기반 유전자 편집 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/보조적인 시장 전망.
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• CRISPR 기반 유전자 편집 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 CRISPR 기반 유전자 편집 시장 : 제품 및 서비스 추정·동향 분석

• 부문 대시보드
• 세계의 CRISPR 기반 유전자 편집 시장 제품 및 서비스 변동 분석
• 세계의 CRISPR 기반 유전자 편집 시장 규모와 동향 분석, 제품 및 서비스별, 2021-2033년
• 제품
  • CRISPR 키트와 시약
  • CRISPR 라이브러리
  • 기타
• 서비스

제5장 CRISPR 기반 유전자 편집 시장 : 용도 추정·동향 분석

• 부문 대시보드
• 세계의 CRISPR 기반 유전자 편집 시장 용도 변동 분석
• 세계의 CRISPR 기반 유전자 편집 시장 규모와 동향 분석(용도별, 2021-2033년)
• 바이오메디컬
  • 치료 개발
  • 질병 진단
• 농업 용도
  • 식물 공학
  • 가축 공학
  • 기타

제6장 CRISPR 기반 유전자 편집 시장 : 최종 용도 추정·동향 분석

• 부문 대시보드
• 세계의 CRISPR 기반 유전자 편집 시장 최종 용도 변동 분석
• 세계의 CRISPR 기반 유전자 편집 시장 규모와 동향 분석, 최종 용도별, 2021-2033년
• 제약·바이오테크놀러지 기업
• 학술연구기관
• 계약 연구기관

제7장 CRISPR 기반 유전자 편집 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2033년
• 지역 시장 대시보드
• 시장 규모, 예측 동향 분석, 2021-2033년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 기업/경쟁 분류
• 전략 매핑
• 기업 시장 상황 분석, 2024년
• 기업 개요/상장 기업
  • Revvity, Inc.
  • Danaher Corporation
  • GenScript
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Tocris Bioscience
  • OriGene Technologies, Inc.
  • Bio-Rad Laboratories
  • Bio-Techne
  • New England Biolabs, Inc.

KSM

영문 목차

영문목차

CRISPR-based Gene Editing Market Summary

The global CRISPR-based gene editing market size was estimated at USD 4.01 billion in 2024 and is projected to reach USD 13.50 billion by 2033, growing at a CAGR of 14.7% from 2025 to 2033. This growth is driven by the rising prevalence of genetic disorders, advancements in research and technology, supportive government initiatives, and increasing investment in biotechnology.

Advancements in CRISPR Technology & Applications

Advancements in CRISPR technology and applications are significantly accelerating market growth by enhancing precision, efficiency, and versatility in gene editing. Since its discovery, the CRISPR-Cas system has evolved beyond basic DNA cutting into a sophisticated genome engineering platform. It is supported by innovations such as high-fidelity Cas variants, base editing, prime editing, and improved delivery mechanisms such as lipid nanoparticles and viral vectors. These improvements have reduced off-target effects, increased editing efficiency, and broadened the scope of treatable conditions. Integration with artificial intelligence (AI) and machine learning has further optimized guide RNA design and target site selection, enabling faster, more accurate development cycles. Technology's adaptability also supports multiplexed editing, allowing simultaneous modification of multiple genes crucial for tackling complex diseases and traits.

These advancements also expand CRISPR into new application areas beyond human therapeutics, including agriculture, industrial biotechnology, diagnostics, and environmental management. In agriculture, CRISPR is being applied to create climate-resilient, pest-resistant, and nutrient-enhanced crops, offering solutions to food security challenges. In diagnostics, CRISPR-based tools such as SHERLOCK and FELUDA enable rapid, low-cost detection of infectious diseases. At the same time, in synthetic biology, CRISPR is used to engineer microorganisms for sustainable biofuel and material production. The widening scope of CRISPR applications, coupled with ongoing technical refinements, is attracting strong investments from pharmaceutical companies, agri-biotech firms, and research institutions. This continual innovation cycle expands the addressable market and strengthens CRISPR's position as a transformative technology platform across multiple industries.

Global CRISPR-based Gene Editing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global CRISPR-based gene editing market based on product & service, application, end use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Products
  • CRISPR Kits & Reagents
  • CRISPR Libraries
  • Others
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Biomedical
  • Therapeutic Development
  • By Indication
  • Genetic Disorders
  • Oncology
  • Ophthalmology
  • Others
  • By Delivery Method
  • Ex Vivo
  • In Vivo
  • Disease Diagnostics
• Agricultural applications
  • Plant Engineering
  • Farm Animals Engineering
  • Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. CRISPR-based Gene Editing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of genetic disorders
    • 3.2.1.2. Growing investments in biotechnology and healthcare research
    • 3.2.1.3. Advancements in CRISPR technology and applications
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Ethical concerns surrounding gene editing
    • 3.2.2.2. High costs associated with CRISPR research and development
• 3.3. CRISPR-based Gene Editing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. CRISPR-based Gene Editing Market: Product & Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global CRISPR-based Gene Editing Market Product & Service Movement Analysis
• 4.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
• 4.4. Products
  • 4.4.1. Products market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. CRISPR Kits & Reagents
    • 4.4.2.1. CRISPR kits & reagents market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. CRISPR Libraries
    • 4.4.3.1. CRISPR libraries market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. CRISPR-based Gene Editing Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global CRISPR-based Gene Editing Market Application Movement Analysis
• 5.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Biomedical
  • 5.4.1. Biomedical market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Therapeutic Development
    • 5.4.2.1. Therapeutic development market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2.2. By Indication
      • 5.4.2.2.1. Genetic Disorders
        • 5.4.2.2.1.1. Genetic Disorders market estimates and forecasts 2021 to 2033 (USD Million)
      • 5.4.2.2.2. Oncology
        • 5.4.2.2.2.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
      • 5.4.2.2.3. Ophthalmology
        • 5.4.2.2.3.1. Ophthalmology market estimates and forecasts 2021 to 2033 (USD Million)
      • 5.4.2.2.4. Others
        • 5.4.2.2.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2.3. By Delivery Method
      • 5.4.2.3.1. Ex Vivo
        • 5.4.2.3.1.1. Ex vivo market estimates and forecasts 2021 to 2033 (USD Million
      • 5.4.2.3.2. In Vivo
        • 5.4.2.3.2.1. In vivo market estimates and forecasts 2021 to 2033 (USD Million
  • 5.4.3. Disease Diagnostics
    • 5.4.3.1. Disease diagnostics market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Agricultural applications
  • 5.5.1. Agricultural applications market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.2. Plant Engineering
    • 5.5.2.1. Plant engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.3. Farm Animals Engineering
    • 5.5.3.1. Farm animals engineering market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5.4. Others
    • 5.5.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. CRISPR-based Gene Editing Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global CRISPR-based Gene Editing Market End Use Movement Analysis
• 6.3. Global CRISPR-based Gene Editing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical & Biotechnology Companies
  • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Contract Research Organizations
  • 6.6.1. Contract research organizations market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. CRISPR-based Gene Editing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Target disease prevalence
    • 7.4.2.4. Regulatory framework
    • 7.4.2.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Target disease prevalence
    • 7.4.3.4. Regulatory framework
    • 7.4.3.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Target disease prevalence
    • 7.4.4.4. Regulatory framework
    • 7.4.4.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Target disease prevalence
    • 7.5.2.4. Regulatory framework
    • 7.5.2.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Target disease prevalence
    • 7.5.3.4. Regulatory framework
    • 7.5.3.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Target disease prevalence
    • 7.5.4.4. Regulatory framework
    • 7.5.4.5. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Target disease prevalence
    • 7.5.5.4. Regulatory framework
    • 7.5.5.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Target disease prevalence
    • 7.5.6.4. Regulatory framework
    • 7.5.6.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Target disease prevalence
    • 7.5.7.4. Regulatory framework
    • 7.5.7.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Target disease prevalence
    • 7.5.8.4. Regulatory framework
    • 7.5.8.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Target disease prevalence
    • 7.5.9.4. Regulatory framework
    • 7.5.9.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Target disease prevalence
    • 7.6.2.4. Regulatory framework
    • 7.6.2.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Target disease prevalence
    • 7.6.3.4. Regulatory framework
    • 7.6.3.5. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Target disease prevalence
    • 7.6.4.4. Regulatory framework
    • 7.6.4.5. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Target disease prevalence
    • 7.6.5.4. Regulatory framework
    • 7.6.5.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Target disease prevalence
    • 7.6.6.4. Regulatory framework
    • 7.6.6.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Target disease prevalence
    • 7.6.7.4. Regulatory framework
    • 7.6.7.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Target disease prevalence
    • 7.7.2.4. Regulatory framework
    • 7.7.2.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Target disease prevalence
    • 7.7.3.4. Regulatory framework
    • 7.7.3.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Target disease prevalence
    • 7.8.2.4. Regulatory framework
    • 7.8.2.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Target disease prevalence
    • 7.8.3.4. Regulatory framework
    • 7.8.3.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Target disease prevalence
    • 7.8.4.4. Regulatory framework
    • 7.8.4.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Target disease prevalence
    • 7.8.5.4. Regulatory framework
    • 7.8.5.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Revvity, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product/Service benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Danaher Corporation
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product/Service benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. GenScript
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product/Service benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Merck KGaA
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product/Service benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Thermo Fisher Scientific, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product/Service benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Tocris Bioscience
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product/Service benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. OriGene Technologies, Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product/Service benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Bio-Rad Laboratories
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product/Service benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Bio-Techne
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product/Service benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. New England Biolabs, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product/Service benchmarking
    • 8.4.10.4. Strategic initiatives

관련자료